About this episode
In this episode, Dr. Marsha Hartman, Fractional CEO of Exodigm Biosciences, shares her journey from epidemiology to leading-edge biotech innovation. She explores how Exodigm’s breakthrough cell analysis technology is advancing personalized medicine and reshaping the future of diagnostics. The conversation dives into the lessons learned from COVID-19, the balance between science and strategy in leadership, and the ethical dimensions of AI in healthcare. Dr. Hartman also reflects on the importance of listening, collaboration, and purpose-driven work in creating meaningful impact across the life sciences.Chapters:00:00 Introduction to Marsha Hartman and Her Journey03:09 The Intersection of Epidemiology and Immunology06:00 Sales and Science: A Unique Blend09:13 COVID-19: A Case Study in Epidemiology and Immunology11:52 The Role of Biomarkers in Personalized Medicine15:02 Exodigm: Transforming Cell Analysis17:58 Marsha's Transition to CEO20:48 Leadership Philosophy and Personal Growth27:27 The Art of Listening in Leadership30:07 Lessons from COVID-19: A Global Experience34:01 The Role of Technology in Healthcare36:12 The Future of Personalized Medicine39:22 Patient Data Ownership and Accessibility42:20 The Ethical Use of AI in Healthcare44:23 Finding Your Purpose and Aligning with OthersGuest Information:Guest's Name: Dr. Marsha L. HartmanGuest's Title/Position: Fractional CEOGuest's Linkedin: https://www.linkedin.com/in/marsha-l-hartman-phd-4b77903b/Company / Affiliation: Exodigm Biosciences https://www.exodigm.com/Guest's Bio: Dr. Marsha L. Hartman is the Fractional CEO of Exodigm Biosciences, a pioneering startup within the General Inception portfolio. At Exodigm, she is leading efforts to revolutionize cellular biology by enabling live single-cell analysis through transcriptomic insights — helping researchers and biomanufacturers work precisely with the cells they need. With a background in epidemiology and extensive leadership experience across diagnostics, biotech, and commercialization, Dr. Hartman brings a strategic and scientific lens to building scalable solutions for the next generation of cell therapy and analysis. Under her leadership, Exodigm is pushing the boundaries of innovation to accelerate discovery and redefine what’s possible in cellular science.Takeaways:Marsha Hartman has a unique background in epidemiology and immunology.She transitioned from academia to sales and marketing in the life sciences.COVID-19 highlighted the importance of understanding immunology and epidemiology together.Biom
